News Quantified

ATXI – avenue therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds [Yahoo! Finance]

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Avenue Therapeutics Announces Reverse Stock Split [Yahoo! Finance]

Avenue Therapeutics Announces Reverse Stock Split

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Form 8-K AVENUE THERAPEUTICS, For: Apr 25

Form 4 AVENUE THERAPEUTICS, For: Apr 16 Filed by: Fortress Biotech, Inc.

Form SC 13D/A AVENUE THERAPEUTICS, Filed by: Fortress Biotech, Inc.

Form 8-K AVENUE THERAPEUTICS, For: Mar 26

Form DEF 14C AVENUE THERAPEUTICS, For: Mar 18

Top News Gainers

6/3 Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain 15.0%

3/30 Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights 8.9%

3/30 Form 10-K AVENUE THERAPEUTICS, For: Dec 31 6.3%

12/11 Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol 4.8%

5/14 Avenue Therapeutics Inc (NASDAQ: ATXI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. 3.3%

6/3 Avenue Therapeutics, Inc. (ATXI) CEO Dr. Lucy Lu Hosts Investor Update Call (Transcript) [Seeking Alpha] 3.3%

8/12 Form 4 AVENUE THERAPEUTICS, For: Aug 08 Filed by: Vazzano Joseph Walter 2.3%

12/31 Form 3 AVENUE THERAPEUTICS, For: Feb 08 Filed by: InvaGen Pharmaceuticals, Inc. 2.3%

11/15 Avenue Therapeutics Inc (NASDAQ: ATXI) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.4%

4/29 Form DEF 14A AVENUE THERAPEUTICS, For: Jun 16 3.2%

Top News Decliners

10/18 Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting -2.6%

2/13 Form 8-K AVENUE THERAPEUTICS, For: Feb 13 -2.5%

2/13 Form 4 AVENUE THERAPEUTICS, For: Feb 12 Filed by: Vazzano Joseph Walter -2.1%

3/2 Form 4 AVENUE THERAPEUTICS, For: Feb 26 Filed by: Herskowitz Neil -1.9%

5/13 Q1/2019 3/31/2019 EPS -0.820 ZacksConsensus -0.440 ActVsEst (0.380) - Miss -1.7%

6/5 Form 4 AVENUE THERAPEUTICS, For: Jun 03 Filed by: Lu Lucy -2.9%

10/28 Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development -3.0%

4/23 Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters -3.5%

8/14 Q2/2019 6/30/2019 EPS -0.430 ZacksConsensus -0.560 ActVsEst 0.130 - Beat -3.6%

3/10 Form 4 AVENUE THERAPEUTICS, For: Mar 09 Filed by: Vazzano Joseph Walter -6.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day